Skip to content
value.today
Sol-Gel Technologies logo

Sol-Gel Technologies

4SG.F
$99 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$19 M
For year ending December-2025
Net income
$-6 M
-31.6% margin
SEC filing
Employees
—

Sol-Gel Technologies in brief

Sol-Gel Technologies is a listed company in the Biotechnology industry, based in Israel. Its last known market value was $99 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $19 M and a net loss of $6 M. Its largest product and service lines by sales in 2025 were Sale of IP and license revenue (96%), Royalty (4%) and Service, Other (under 1%). By market, the largest shares of its 2025 sales came from USA (86%), Canada (9%) and Switzerland (4%). Its shares trade under the symbol 4SG.F (Frankfurt).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Sol-Gel Technologies timeline

1 events, 2018
  1. 2018
  2. 🔔
    · approximate
    Initial public offering on Frankfurt

Events of Sol-Gel Technologies from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$100 M$201 M$301 M$402 M2020202120222023

World rank over time

▼ down 9,115 places since 2020
2020-01-01: #12593#12,59320202021-01-01: #15025#15,02520212022-01-07: #19520#19,52020222022-12-25: #21460#21,46020222023-07-30: #21708#21,7082023

Rank in Israel: #111 (Jan 2020) · #159 (Jan 2021) · #236 (Jan 2022) · #241 (Dec 2022) · #251 (Jul 2023)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-31.6%
Operating margin
-38.9%
Return on equity
-26.9%
Liabilities / assets
23.8%
Revenue growth
+68.0%
R&D / revenue
117.6%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-32M$0MFY18Fiscal year ending Dec 2019: revenue $23M, net income $-25M$23MFY19Fiscal year ending Dec 2020: revenue $9M, net income $-29M$9MFY20Fiscal year ending Dec 2021: revenue $31M, net income $3M$31MFY21Fiscal year ending Dec 2022: revenue $4M, net income $-15M$4MFY22Fiscal year ending Dec 2023: revenue $2M, net income $-27M$2MFY23Fiscal year ending Dec 2024: revenue $12M, net income $-11M$12MFY24Fiscal year ending Dec 2025: revenue $19M, net income $-6M$19MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$19M+68.0%$-8M$-6M-31.6%
Dec 2024$12M+644.5%$-12M$-11M-91.7%
Dec 2023$2M-60.1%$-29M$-27M-1757.4%
Dec 2022$4M-87.6%$-16M$-15M-384.5%
Dec 2021$31M+256.6%$3M$3M10.3%
Dec 2020$9M-61.7%$-30M$-29M-334.0%
Dec 2019$23M+17515.4%$-26M$-25M-107.5%
Dec 2018$0M—$-34M$-32M-24769.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$0M$0M$0M$-2.19—
Dec 2024$-14M$0M$-14M$-3.79—
Dec 2023$-18M$0M$-18M$-10.01—
Dec 2022$-9M$0M$-10M$-0.65—
Dec 2021$-8M$0M$-8M$0.14—
Dec 2020$-25M$0M$-26M$-1.30—
Dec 2019$-23M$1M$-23M$-1.26—
Dec 2018$-23M$1M$-25M$1.80—

SEC filings

Official filings of Sol-Gel Technologies with the US Securities and Exchange Commission.

Annual results

Revenue
$19 M
Operating income
$-8 M
Net income
$-6 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$30 M
Total liabilities
$7 M
Total equity
$23 M

As of December-2025

Insider trading at Sol-Gel Technologies#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
7.7 M
33 purchases, 1 insider
Sold, 12 months
0
0 sales, 0 insiders
Net, 12 months
7.7 M
open market only
Insiders on file
1
since
$2.9 M$0Jan 2026: bought $302 K (5 trades), sold $0 (0 trades)Jan 26Feb 2026: bought $24 K (2 trades), sold $0 (0 trades)FebMar 2026: bought $2.9 M (2 trades), sold $0 (0 trades)MarMay 2026: bought $332 K (3 trades), sold $0 (0 trades)MayJul 2026: bought $287 K (6 trades), sold $0 (0 trades)JulAug 2026: bought $2.9 M (6 trades), sold $0 (0 trades)AugSep 2026: bought $1.0 M (9 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Sol-Gel Technologies: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Opaleye Management Inc.10% ownerBuyindirect+1,49365.9598 Klocal540,000Form 4
filed Opaleye Management Inc.10% ownerBuyindirect+1,63166.80109 Klocal538,507Form 4
filed Opaleye Management Inc.10% ownerBuyindirect+3,09768.71213 Klocal536,876Form 4
filed Opaleye Management Inc.10% ownerBuyindirect+3,39068.74233 Klocal533,308Form 4
filed Opaleye Management Inc.10% ownerBuyindirect+47169.3733 Klocal533,779Form 4
filed Opaleye Management Inc.10% ownerBuyindirect+91869.5264 Klocal527,818Form 4
filed Opaleye Management Inc.10% ownerBuyindirect+2,10068.98145 Klocal529,918Form 4
filed Opaleye Management Inc.10% ownerBuyindirect+90068.9562 Klocal526,900Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars

Markets and events: Sol-Gel Technologies#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
135,062
4.8% of shares · 3.23 days to cover

Fails to deliver

  • : 172 shares at $68.66
  • : 212 shares at $68.18
  • : 59 shares at $68.19
  • : 264 shares at $69.45
  • : 413 shares at $68.30

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Sol-Gel Technologies scorecard#

Passes 8 of the 14 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (2 of 5). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 6
    • ✓Revenue grew in the newest year68.0%Revenue up 68.0% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years71.0%71.0% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median71.0%71.0% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-2.19 vs -3.79Diluted EPS -2.19 in fiscal 2025 against -3.79 the year before (report's currency).
    • ✓Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$29 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability2 of 5
    • ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-38.9%-38.9% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-23.7%-23.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-38.9%-38.9% in fiscal 2025 against -418.6% in 2022.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities4.4×Current ratio 4.37 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.0%Diluted shares down 0.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Sol-Gel Technologies's statements, beside the median of Biotechnology.

Sol-Gel Technologies: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-38.9%-60.5%
Net margin-31.6%-68.9%
Return on equity-23.7%-61.0%
Revenue growth, 3 years a year71.0%12.9%
Revenue growth68.0%15.8%
Free cash flow margin1.4%-61.5%

5of 7on the Piotroski tests of financial strength

  • Net loss of $6 million, the 4th loss-making year in a row.

Sol-Gel Technologies: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Sol-Gel Technologies: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue19121.63.9318.8230.10.2—
Research and development23182413202841282617
Selling and marketing00.00.00.0r0.00.00.00.00.0—
General and administrative4.25.77.47.48.5118.35.56.03.7
Operating income−7.5−12−29−163.0−30−26−34−32−21
Income before tax————3.2−29−25−32r−32—
Income tax000—000.0———
Net income including minority interests−6.1−11−27−153.2−29−25−32−32−21
Net income attributable to shareholders−6.1−11−27−153.2−29−25−32−32−21
Earnings per share, basic-2.19-3.79r-10.01r-0.650.14-1.30r-1.26r1.805.023.30
Earnings per share, diluted-2.19-3.79r-10.01r-0.650.14-1.30r-1.26r1.805.023.30
Shares, weighted average (basic)2.82.8r2.7r23232320———
Shares, weighted average (diluted)2.82.8r2.7r23242320186.36.3
Balance sheet
Cash and cash equivalents11197.512207.19.45.35.07.0
Short-term investments134.4208.71.7224157——
Receivables2.03.60.40.1r132.24.1———
Other current assets1.03.82.81.5r0.81.11.33.01.5r0.5
Current assets2731414357535666118.3
Property, plant and equipment0.10.20.40.71.11.82.32.62.30.8
Right-of-use (leased) assets1.01.41.70.91.51.92.0———
Non-current assets2.94.64.13.6125.85.53.74.82.7
Total assets30364547695961701511
Accounts payable0.71.30.20.30.81.21.72.90.50.7
Current liabilities6.25.34.53.3126.06.54.96742
Lease liabilities (non-current)0.50.91.20.10.81.31.4———
Non-current liabilities0.91.72.11.11.92.32.30.90.80.7
Total liabilities7.17.06.64.4148.38.85.86842
Retained earnings−237−231−220−193−178−181−152−127−95−64
Shareholders' equity2329394256515264−53−31
Total liabilities and equity30364547695961701511
Shares outstanding2.82.8r2823232320196.36.3
Cash-flow statement
Depreciation and amortization0.10.20.30.60.90.90.90.80.50.4
Share-based compensation0.10.81.91.50.71.22.64.74.01.0
Cash from operating activities0.3−14−18−9.5−7.7−25−23−23−24−18
Capital expenditure−0.0−0.0−0.1−0.2−0.1−0.4−0.6−1.1−1.9−0.4
Cash from investing activities−8.627−9.71.720−2.716−55−5.9−0.4
Cash from financing activities0.00220.00.82611792820
Exchange-rate effect on cash————−0.1−0.0−0.10.00.1−0.0
Change in cash−8.413−5.7−7.613−1.54.10.7−2.01.1
Report20-F20-F20-F20-F20-F20-F20-F/A20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Sol-Gel Technologies sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Sale of IP and license revenue$19 M96%
  • Royalty$1 M3.6%
  • Service, Other$0 M0.4%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Sol-Gel Technologies operates: 5 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Sol-Gel Technologies: countries of operation
CountryPresenceRevenue there
🇮🇱 IsraelHeadquarters—
🇺🇸 USA$17 M86%
🇨🇦 Canada$2 M8.7%
🇨🇭 Switzerland$1 M3.7%
🇨🇳 China$0 M0.1%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

How Sol-Gel Technologies compares in Biotechnology

  • Revenue$19 M · higher than 50% of 647
  • Net margin-31.6% · higher than 57% of 408
  • Revenue growth68.0% · higher than 79% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Sol-Gel Technologies🇮🇱$99 M—-31.6%+68.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Sol-Gel Technologies? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Sol-Gel Technologies's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Sol-Gel Technologies? Suggest a correction